Although IL‐6 also plays a key role in depression pathology, IL‐6‐targeted approaches (e.g., tocilizumab for residual depression) show inconsistent results and may even worsen mood in some patients, underscoring the need for precision therapy based on immune profiles [695]. Here, IL6 is linked to major depressive disorder.